DOW JONES21,162.29-754.87 -3.44%
S&P 5002,489.12-95.47 -3.69%
NASDAQ7,452.19-247.91 -3.22%

Wells Fargo Upgrades NovoCure to Overweight, Raises Price Target to $90

Wells Fargo analyst Lawrence Biegelsen upgrades NovoCure (NASDAQ:NVCR) from Equal-Weight to Overweight and raises the price target from $85 to $90.

Benzinga · 03/05/2020 12:05

Wells Fargo analyst Lawrence Biegelsen upgrades NovoCure (NASDAQ:NVCR) from Equal-Weight to Overweight and raises the price target from $85 to $90.